1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Too Early To Call The End Of Biotech Wilderness

Reports Of Emergence From Biotech’s Dark Age May Have Been Exaggerated

 
• By Andy Smith

To emerge from a wilderness period or biotech winter where generalist investors shun the sector, biotech’s good news needs to outweigh the bad and be attractively priced. We may not be there yet.

Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

In one of David Poyer’s novels on the career of a fictional US naval officer, a regional war erupts and politicians consult with academics on how such conflicts are resolved. While also relevant today with wars in Europe and the Middle East, I wondered if there were correlates like attrition, successes and failures with the end of what I have termed the biotech wilderness period. (Also see "Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness" - Scrip, 26 September, 2023.) The omens for a definitive answer are not good. Academic forecasters have toiled for many years without success on historical stock and index data to create algorithms that attempt to predict when wilderness and bubble periods start and end. This failure is partly because stock markets are complex systems where investors make irrational individual decisions, while at the same time, different momentum investments are made just because many others have done the same thing.

However, merger and acquisition (M&A) activity has always driven the biotech sector and the momentum and impetus have been building...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

Stock Watch: Q2 Earnings Blowouts Resume At AstraZeneca And GSK

 
• By Andy Smith

While second-quarter revenue growth bolstered both the UK’s big pharma companies, some of that growth may have been catch-up from the weak first quarter. This resulted in sales of even seasonally weak off-patent products, growing.

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By Andy Smith

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

 
• By Andy Smith

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

More from Business

BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam

 
• By Manas Mishra

Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

Amgen Plans AI Investment Amid Strong Sales Growth

 
• By Alaric DeArment

CEO Robert Bradway expressed support on the company’s Q2 earnings call for lower drug prices but said it was “premature” to comment in detail on particular proposals.